1-3 of 3
Lars C. Borris, MD
Close
Sort by
Journal Articles

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Richard J. Friedman, MD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Tiemo J. Bandel, MD, Eva Muehlhofer, MD, Frank Misselwitz, MD, William Geerts, MD
Journal: Blood
Blood (2007) 110 (11): 6.
https://doi.org/10.1182/blood.V110.11.6.6
Published: 2007
Journal Articles

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

Michael R. Lassen, MD, Alexander G.G. Turpie, MD, Nadia Rosencher, MD, Lars C. Borris, MD, Walter Ageno, MD, Jay R. Lieberman, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 308.
https://doi.org/10.1182/blood.V110.11.308.308
Published: 2007
Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 903.
https://doi.org/10.1182/blood.V108.11.903.903
Published: 2006